Marcello C Laurenti
Overview
Explore the profile of Marcello C Laurenti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
178
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mohan S, Christie H, Laurenti M, Egan A, Bailey K, Cobelli C, et al.
J Clin Endocrinol Metab
. 2025 Jan;
PMID: 39758010
Context: Defects in insulin secretion and action contribute to the progression of prediabetes to diabetes. However, the contribution of α-cell dysfunction to this process has been unclear. Objective: Understand the...
2.
Dyer R, Laurenti M, Christie H, Mohan S, Egan A, Dalla Man C, et al.
Am J Physiol Endocrinol Metab
. 2024 Dec;
328(1):E62-E68.
PMID: 39653064
Accurate measurement of glucagon concentrations in a variety of conditions is necessary for subsequent estimation of glucagon secretion. Glucagon arises in the α-cell as a product of proglucagon processing. Modern...
3.
Zeini M, Laurenti M, Egan A, Muthusamy K, Ramar A, Vella E, et al.
Diabetes
. 2024 Jun;
73(9):1440-1446.
PMID: 38869455
Article Highlights:
4.
Voigt J, Lauritsen K, Pedersen S, Hansen T, Moller N, Jessen N, et al.
Basic Clin Pharmacol Toxicol
. 2024 Feb;
134(5):643-656.
PMID: 38409617
Aims: Sodium glucose co-transporter-2 (SGLT2) inhibition lowers glucose levels independently of insulin, leading to reduced insulin secretion and increased lipolysis, resulting in elevated circulating free fatty acids (FFAs). While SGLT2...
5.
Karakaplan N, Song Y, Laurenti M, Vella A, Jensen M
J Clin Endocrinol Metab
. 2023 Sep;
109(2):e596-e601.
PMID: 37758511
Context: The impact of insulin, particularly exogenous hyperinsulinemia, on insulin secretion in humans is debated. Objective: We assessed the effects of exogenous hyperinsulinemia on insulin secretion and whether the response...
6.
Welch A, Farahani R, Egan A, Laurenti M, Zeini M, Vella M, et al.
J Clin Invest
. 2023 Sep;
133(22).
PMID: 37751301
BACKGROUNDProglucagon can be processed to glucagon-like peptide1 (GLP-1) within the islet, but its contribution to islet function in humans remains unknown. We sought to understand whether pancreatic GLP-1 alters islet...
7.
Schembri Wismayer D, Laurenti M, Song Y, Egan A, Welch A, Bailey K, et al.
Am J Physiol Endocrinol Metab
. 2023 Jun;
325(2):E119-E131.
PMID: 37285600
Elevated fasting free fatty acids (FFAs) and fasting glucose are additively associated with impaired glucose tolerance (IGT) and decreased β-cell function [quantified as disposition index (DI)]. We sought to examine...
8.
Faggionato E, Laurenti M, Vella A, Dalla Man C
IEEE Trans Biomed Eng
. 2023 Apr;
70(9):2733-2740.
PMID: 37030857
Objective: To date, the lack of a model of glucagon kinetics precluded the possibility of estimating and studying glucagon secretion in vivo, e.g., using deconvolution, as done for other hormones...
9.
Farahani R, Egan A, Welch A, Laurenti M, Cobelli C, Dalla Man C, et al.
Diabetes
. 2022 Dec;
72(4):449-454.
PMID: 36562995
Data from transgenic rodent models suggest that glucagon acts as an insulin secretagogue by signaling through the glucagon-like peptide 1 receptor (GLP-1R) present on β-cells. However, its net contribution to...
10.
Kohlenberg J, Laurenti M, Egan A, Schembri Wismayer D, Bailey K, Cobelli C, et al.
Diabetologia
. 2022 Sep;
66(1):201-212.
PMID: 36112169
Aims/hypothesis: People with isolated impaired fasting glucose (IFG) have normal beta cell function. We hypothesised that an increased glucose threshold for beta cell secretion explains IFG. Methods: We used graded...